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ackground: Outbreaks of low-pathogenic Avian Influenza virus H9N2 (AIV-H9N2) occurred in 
poultry industry in Pakistan in 1998 and caused serious economic losses. Since then, many of the 
AIV-H9N2 vaccines have been introduced to Pakistani market to control the virus, however, it is 
still circulating all over the country. Therefore, the purpose of the study was to prepare and 
evaluate different adjuvant containing vaccines using local isolate of AIV-H9N2 in broiler birds. 
Methods: Three vaccines; Alum precipitated (AP-AIV), Aluminum hydroxide gel (AH-AIV) and Oil 
based (OB-AIV) were prepared in the laboratory and injected into broiler birds at 7th and 14th day of age. 
There were four groups of birds including one control group. To evaluate the serological response of the 
birds to vaccines, serum antibody titers were measured using haemagglutination inhibition test (HI). 
Vaccinated and control birds were challenged with AIV-H9N2 and virus shedding was determined from 
trachea and cloacal swabs by HI.  
Results: Out of the three prepared OB-AIV with hydrophile lypophile balance (HLB) values 5.37, 8.01 and 
9.01, the vaccine with HLB value of 8.01 was the most stable. Each of the adjuvant containing vaccine was 
effective in inducing high HI antibody titers. However, OB-AIV was found to be the most effective in 
inducing a significantly higher (P<0.05) HI titer as compared to that of AP-AIV and AH-AIV each. No 
significant difference was observed between the HI titers induced by AP-AIV and AH-AIV. All the 
vaccines also showed effective protection against AIV-H9N2 challenge in vaccinated birds.  
Conclusion: In conclusion, this study reports the successful preparation and evaluation of adjuvant 
containing inactivated AIV-H9N2 vaccines. OB-AIV formulation was found to be most effective to 
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Introduction  
Avian Influenza (AI) is a viral infection of poultry. It has 
emerged as a disease with significant potential to cause 
extensive loses to commercial poultry production [1,2]. 
In 1998 an outbreak of unknown etiology was reported 
in heavily populated region in Mansehra and Abbotabad 
districts in Northern Pakistan. The causative agent was 
confirmed as AI virus (AIV) subtype H9N2 (AIV-
H9N2) [3]. Later on other outbreak AIV-H9N2 in 
broilers and layers in Karachi and layers in Abbotabad 
were reported in 1998 and 1999. The morbidity was 100 
percent and mortality was up to 50 percent [4]. Later on 
outbreaks of LPAI (H9N2) and highly pathogenic 
Influenza virus (HPIV) occurred in different parts of the 
country in different times [5-7]. The latest outbreak of 
LPAI (H9N2) has been reported in Pakistan in 2015 [4]. 
In recent years, due to the continuous rapid spread of 
H9N2 virus among domestic birds, it has gained 
significant importance [8-10]. This virus persists in 
chicks and spreads to non-affected flocks through fecal 
oral route without showing severe clinical signs [11]. 
Co-infection with other viruses like infectious 
bronchitis is one of the most important reasons for the 
high mortality resulted from H9N2 virus infection [4]. 
The emergence of this new subtype of AIV might be due 
to mutation or brought in this country by migratory 
birds. AIV are characterized by extreme variation in 
antigenicity. Minor changes in amino acid sequence of 
surface proteins can occur as a result of point mutation. 
The 8-segmented RNA of AIV is also a cause of this 
genetic re-assortment [1].  
AI is a viral problem so it can only be controlled by 
bio-security measures or mass vaccination program. 
Effective vaccines are required for the protection against 
AIV. An effective vaccine depends not only on the 
presence of appropriate antigen, but also on the antigen 
delivery system i.e. the presence of adjuvants such as 
alum, microspheres, liposomes, immunostimulating 
complexes (ISCOM) or emulsions to stimulate and 
enhance the immune response against that pathogen 
[11]. Adjuvant increases the life and immunogenicity of 
a vaccine. AIV-H9N2 induced outbreaks are responsible 
for consternation to the poultry farmers. Effective and 
economical vaccines which can provide long term 
immunogenicity are the need of time. Therefore the 
present project was designed to prepare different 
adjuvant containing AIV-H9N2 vaccines and compare 
their efficacy in broilers.  
Methods 
Characterization of the virus 
AIV-H9N2 virus was kindly provided by Olympia 
Laboratory Lahore and was inoculated in 9-days-old 
chicken embryo for the propagation via allantoic sac 
route. Allanto-amniotic fluid (AAF) and EID50 was 
calculated according to Reed and Muench method [12] 
and OIE manual [13]. AAF was harvested after 48 hours 
post inoculation (PI). The AIV-H9N2 suspension in the 
AAF was titrated using haemagglutination test (HA) as 
described by [14]. The virus was characterized by virus 
neutralization test and haemagglutination inhibition 
test (HI) using known serum against AIV-H9N2, AIV-
H6N2 and AIV-H7N3, as described by [14].  The virus 
was inactivated by formalin (0.12%) at 37oC for 48 
hours. The inactivation of the virus was confirmed by 
testing no HA activity after three blind passages in 
embryonated chicken eggs. 
Vaccines Preparation 
Three vaccines; Alum precipitated AIV vaccine, 
Aluminum hydroxide gel AIV vaccine and Oil based 
AIV vaccine were prepared following the methods 
described by [15]. 
Alum precipitated AIV vaccine (AP-AIV) 
The AAF (EID50 10-8.3) was admixed with aluminum 
potassium sulfate solution so as to have final 1g/kg 
concentration. The pH was adjusted to 7.4 and was 
incubated at room temperature for 24 hours. 
Aluminum hydroxide gel AIV vaccine (AH-AIV) 
AH-AIV was prepared by adding 250ml of 50g/l of 
aluminum sulfate solution into 100ml of 50g/l of sodium 
hydroxide solution whilst stirring vigorously. The white 
precipitate formed was centrifuged at 600xg. After 
washing twice with distilled water the compact pellet 
was re-suspended in 250ml of normal saline to form 
aluminum hydroxide gel. The gel was stored at 4oC. 
Equal volumes of AAF (EID50 10-8.3) was admixed with 
Aluminum hydroxide suspension. 
Oil based AIV vaccine (OB-AIV) 
OB-AIV was prepared according to hydrophile 
lypophile balance (HLB) values. The HLB values of the 
vaccines were fixed at 5, 8 and 9. These values helped in 
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determining the amount of Span 80 and Tween 80 in the 
vaccine by using following formula [16].  
Xa+Yb= HLB value for the vaccine 
X= Amount of the Span 80 used in the oil base 
preparation 
Y= Amount of Tween 80 used in the oil base preparation 
A= HLB value of span 80= 4.3 (constant) 
B= HLB value of Tween 80= 15 (constant) 
By using above mentioned formula amounts Span 80 
and Tween 80 were calculated for HLB 5.37, 8.01and 
9.01. According to the calculated values three 
compositions of oil base were tried (Table 1).  
The AAF (EID50 10-8.3) was admixed with oil base at 1:4 
ratio. The vaccines were stored at 4oC for stability test.  
HLB value Span 80 Tween80 Liquid 
Paraffin 
5.37 9 ml 1 ml 90 ml 
8.01 6.5 ml 3.5 ml 90 ml 
9.01 5.6 ml 4.4 ml 90 ml 
Table 1: Quantities of the components used for the preparation of oil 
base at different HLB values 
Experimental Plan for the vaccination study 
In this experiment 60 broilers birds (one day old) were 
divided in to four groups; A, B, C and D (each group 
comprising 15 birds). The birds in groups A, B and C 
were vaccinated with OB-AIV, AP-AIV and AH-AIV 
respectively at 7th day of age. The birds of group B and C 
were boosted at 14th day of age with AP-AIV and AH-
AIV respectively. Each vaccine was injected 
subcutaneously at dose rate of 0.5ml per bird (at the neck 
region), while birds of group D were kept as non-
vaccinated control. 
Experimental plan for the challenge study 
Eight birds from each group were challenged at 30 days 
post vaccination. Each bird was inoculated by intra nasal 
route with 0.1 ml of AIV-H9N2 containing AAF (EID50 
10-6). To determine virus shedding, tracheal and cloacal 
swabs were collected in nutrient broth at 2, 4 and 6 days 
post challenge. To reduce bacterial contamination, 
samples were treated with antibiotics. Each sample was 
inoculated to the 9 days old embryonated eggs via 
allantoic sac route to determine virus titer (EID50) using 
Reed and Muench method.  
Collection of serum sample 
Blood samples were collected from each bird on 5, 14, 
21, 28, 35 and 42 days of age. The sera were isolated and 
stored in properly labeled plastic vial at -20oC till 
processing for HI test.  
Haemagglutination Inhibition test 
The HI antibody titer was determined following the 
method described by [14] by using 4 HA unit titer of 
inactivated virus in AAF. The HI titer of each sample 
was expressed as the highest dilution of serum showing 
inhibition of HA activity of the virus. Geometric mean 
titer (GMT), cumulative GMT (CGMT) and standard 
deviation (STD) of HI antibodies of each group was 
tabulated and compared as described by Villegas and 
Purchase [17].  
The statistical significance of the data was determined 
by using Student's t test. Results were considered to be 
statistically significant if the comparison gave a P value 
of <0.05.  
Results 
Three different adjuvant containing AIV-H9N2 (EID50 
10-8.3) vaccines when prepared and injected in broilers, 
induced neutralizing antibodies. The AP-AIV and AH-
AIV induced higher levels of HI antibodies in the 
vaccinated birds when primed at 7th day of age and 
boosted the birds with the respective vaccine at 14th day 
of age. The antibodies reached to the peak level at the 
4th-5th week of age, then started declining.  
OB-AIV was prepared according to required HLB 
values of the oil base. It was observed that vaccine 
prepared with HLB value 8.05 was the most stable. In the 
vaccine prepared using HLB value 9.01, the liquid phase 
was separated at the top and oil phase at the bottom. 
While the vaccine prepared using HLB value 5.37, liquid 
phase was separated at the bottom and the milky white 
oily phase at the top. The birds vaccinated with OB-AIV 
showed high and consistent HI titer till 6th week of age 
(Table 2, Figure 1) as compared to birds of group B and 
CGMT induced by OB-AIV, AP-AIV and AH-AIV were 
129.18+ 81.1, 67.74+ 40.5 and 63.56 +36.13 respectively 
(Table 3). The responses induced by OB-AIV was found 
significantly different (P<0.05) from that of AP-AIV and 
AH-AIV (Figure 2). However the antibody titers 
induced by AP-AIV and AH-AIV were not significantly 
different from each other. 
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To determine that birds were protected 30 days post 
vaccination 8 birds from each group were challenged 
with AIV-H9N2 (EID50 10-6). Birds from each 
vaccination group were found protected after challenge 
with virus as compared to control unvaccinated birds. 
No virus was recovered from the tracheal or cloacal 
swabs collected from the vaccinated birds, while virus 
was detected in all tracheal and cloacal swabs collected 




Geometric mean titer 
Control OB-AIV AP-AIV AH-AIV 
5 0 0 0 0 
14 0 26  42.2 39.4 
21 0 128 68.6 59.7 
28 0 238.9 78.8 73.3 
35 0 169 128 119.4 
42 0 84 21.1 26.0 
Table 2: Geometric mean titers of different vaccinated groups with 
AIV-H9N2 vaccines; OB-AIV: Oil based Avian Influenza (H9 type) 
virus vaccine. AP-AIV: Alum precipitated Avian Influenza (H9 type) 
virus vaccine. AH-AIV: Aluminum Hydroxide containing Avian 
Influenza (H9 type) virus vaccine 
 
Figure 1: Antibody response of the broilers in response to adjuvant 
containing AIV-H9N2 vaccines; OB-AIV: Oil based Avian Influenza 
(H9 type) virus vaccine. AP-AIV: Alum precipitated Avian Influenza 
(H9 type) virus vaccine. AH-AIV: Aluminum Hydroxide containing 
Avian Influenza (H9 type) virus vaccine. STD: Standard error 
 
Figure 2: Comparative efficacy of adjuvant containing AIV-H9N2 
vaccines in broilers; OB-AIV: Oil based Avian Influenza (H9 type) 
virus vaccine. AP-AIV: Alum precipitated Avian Influenza (H9 type) 
virus vaccine.  AH-AIV: Aluminum Hydroxide containing Avian 
Influenza (H9 type) virus vaccine. STD: Standard error 
Vaccines OB-AIV AP-AIV AH-AIV 
CGMT 129.18 63.56 67.74 
STD 81.1 36.13 40.56 
Table 3: Cumulative geometric mean titers (CGMT) of different 
vaccinated groups with Avian Influenza (H9 type) virus vaccines; OB-
AIV: Oil based Avian Influenza (H9 type) virus vaccine. AP-AIV: 
Alum precipitated Avian Influenza (H9 type) virus vaccine. AH-AIV: 
Aluminum Hydroxide containing Avian Influenza (H9 type) virus 
vaccine. STD: Standard error. 
Discussion  
AIV- H9N2 virus is a low pathogenic influenza virus and 
cause severe economic losses to poultry farmers. H9N2 
virus can pose a significant zoonotic threat like H5N1 
[18-20]. Vaccination is the only preventive measure 
against the disease and effective vaccines are required for 
the protection against AIV. An effective vaccine 
depends not only on the presence of appropriate 
antigen, but also on the antigen delivery system. Most 
soluble proteins and peptides are weakly immunogenic 
and require the presence of adjuvants such as alum, 
microspheres, liposomes, ISCOM or emulsions to 
stimulate the relevant immune response [21]. To 
establish a long term memory response adjuvants are 
essential. Adjuvants enhance the immunogenicity when 
added in the vaccines. An antigen driven immune 
response is initiated when antigen is present and 
terminated once the antigen is eliminated. Non adjuvant 
containing inactivated AI vaccines are presumably 
absorbed from the inoculation site without providing a 
suitable stimulus to the immunocompetent cells [22].  
In the present study the comparative efficacy of three 
different adjuvants containing AIV-H9N2 vaccines 
were determined. All the three vaccines have induced 
high antibody titers in chicken against AIV-H9H2. The 
purpose of incorporating adjuvants is to promote the 
immune response to the antigen of interest. Different 
studies have shown that adjuvant action results from a 
depot effect, due to which the duration of the interaction 
between cells and antigen is prolonged. Emulsion 
adjuvants has similar antigen releasing properties [21]. 
An emulsion is defined as a dispersion of two immiscible 
liquids in which one liquid which is called as dispersed 
phase is mixed into a second liquid which is called as 
continuous phase. In vaccine preparation, dispersed 
phase is water (antigenic media) and continuous phase 
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is oil. In order to stabilize the emulsions, surfactants are 
added. Surfactants can be defined by their HLB value 
which gives information on their relative affinity for the 
both phases. HLB is an expression of relative 
simultaneous attraction of an emulsifier for water and 
oil [23]. Stability of a vaccine is very important and HLB 
is one of the various parameters which can influence on 
it. Different kind of emulsions can be formulated using 
different HLB values of the surfactant. Antigen release 
rate also varies widely among emulsions containing 
emulsifiers with different HLB values, hence it is very 
important to choose a suitable HLB value for 
preparation of a stable vaccine which can give a longer 
immunity by releasing antigen for a longer period of 
time [24].  
In this study emulsion-type adjuvants containing 
vaccine; OB-AIV was prepared with different HLB 
values and HLB value 8.01 of the oil base was found the 
most stable. OB-AIV induced the highest levels of HI 
antibodies among the three vaccines used in the study 
(Table 2). Single dose of OB-AIV at the age of 7 days was 
found effective and induced high titers for longer period 
of time as compared to other two vaccines. AP-AIV or 
AH-AIV also induced higher levels of HI antibodies in 
vaccinated birds when primed at 7th day of age and 
boosted the birds with the same vaccine at 14th day of age 
(Table 2, Figure 1). The high levels of antibodies were 
detected till 4th -5th week of age. Stephenson et al found 
that two doses of inactivated vaccine given three weeks 
apart were safe and well tolerated. Antibody response to 
one dose of vaccine is poor so primed patients should be 
protected with single dose of same vaccine [25]. Yaqub 
et al used alum precipitated vaccine which could induce 
detectable levels of HI antibodies in vaccinated birds on 
7th day post vaccination (PV) and did not display 
protection on 4th week PV [26]. In other study, Khan et 
al also found the same results with alum precipitated 
vaccine [27]. The birds which were vaccinated for only 
one time showed very low HI antibody titer as compared 
to those which were vaccinated two times after two 
weeks intervals. Aluminum hydroxide and other 
aluminum salts moderately enhance the antibody level 
[28].  
The most preferable method to control AIV infection 
is the use of inactivated vaccines, worldwide [24-29]. 
This strategy not only provides long term immunity to 
the birds but also avoids the antigenic shift and/or drift 
in  the  virus  genome  which  prevents  genetic  re- 
assortment  [28,  29].  Adjuvants  (oil  based  or  non-oil 
based)  containing  vaccine  when  injected  induced  a 
depot at the inoculation site and cause irritation, recruit 
immune  competent  cells  (lymphocytes)  and  antigen 
presenting cells (APC) at the injection site for a longer 
period  of  time  [29].  As  a  result  higher  levels  of 
antibodies titers can be achieved which is not in the case 
of  non-adjuvant  containing  vaccine  [30-33].  Upon 
challenge, with the AIV-H9N2, all the vaccinated birds 
were  protected  from  infection  which  showed  that 
adjuvant  containing  vaccines  give  protection  for  a 
longer period of time. 
 It  is  concluded  from  the  experiment  that  adjuvant 
containing  vaccines  are  effective  in  inducing  high  HI 
titers  in  broilers.  Comparison  of  different  adjuvant 
containing  vaccines  have  shown that  oil  based  vaccine 
was the highly efficient. The immune response produced 
in  birds  vaccinated  with  OB-AIV  was  significantly 
higher than other vaccines. The antibody titer induced 
by AP-AIV and AH-AIV were not significantly different 
from  each  other.  In  summary,  the  results  of  present 
study  demonstrate  that  a  protective  immune  response 
can be achieved by using H9N2 inactivated vaccines in 
broiler  birds,  suggesting  that  these  vaccines  could  be 
used  to  prevent  and  control  AIV-H9N2  in  poultry 
industry.  It  is  also  suggested  from  the  results  of  this 
study that a single dose of oil based AIV vaccine, at the 
early  age  of  broiler  birds,  can  be  effective  to  prevent 
outbreaks of AIV-H9N2 for a longer period of time. 
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